Terns Pharmaceuticals appoints Amy Burroughs as CEO and director effective Feb 7, 2024

Terns Pharmaceuticals, Inc.

Amy Burroughs appointed CEO effective Feb 7, 2024; Jill Quigley becomes independent director after serving as Interim Senior Advisor.
Burroughs receives $625k salary, 50% target bonus, option to buy 1.25M shares, and 150k RSUs with price milestones at $15 and $20.
Burroughs previously CEO of Cleave Therapeutics, brings over 25 years experience in biotech and commercial roles.
Equity awards previously granted to Quigley will continue to vest based on her director service.

item 5.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Amy Burroughs

Chief Executive Officer and Director

TERN · Terns Pharmaceuticals, Inc.

Effective: 2024-02-07
Filed: February 7, 2024, 6:59 PM ET

pursuant to which Ms. Burroughs will serve as the Chief Executive Officer of Terns and has been appointed and elected as a member of the Board of Directors of Terns (the “Board”), effective as of February 7, 2024

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Amy Burroughs was appointed as Chief Executive Officer and Director at Terns Pharmaceuticals, Inc..

Action: appointed
Role: Chief Executive Officer and Director

Exact text from the filing

pursuant to which Ms. Burroughs will serve as the Chief Executive Officer of Terns and has been appointed and elected as a member of the Board of Directors of Terns (the “Board”), effective as of February 7, 2024

View on SEC.gov

Terns Pharmaceuticals, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-24-026712

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.